Details

Autor(en) / Beteiligte

• Revello, Maria Grazia
• Lazzarotto, Tiziana
• Guerra, Brunella
• Spinillo, Arsenio
• Ferrazzi, Enrico
• Kustermann, Alessandra
• Guaschino, Secondo
• Vergani, Patrizia
• Todros, Tullia
• Frusca, Tiziana
• Arossa, Alessia
• Furione, Milena
• Rognoni, Vanina
• Rizzo, Nicola
• Gabrielli, Liliana
• Klersy, Catherine
• Gerna, Giuseppe

Titel

A Randomized Trial of Hyperimmune Globulin to Prevent Congenital Cytomegalovirus

Ist Teil von

• The New England journal of medicine, 2014-04, Vol.370 (14), p.1316-1326

Ort / Verlag

Waltham, MA: Massachusetts Medical Society

Erscheinungsjahr

2014

Quelle

MEDLINE

Beschreibungen/Notizen

• Congenital infection with cytomegalovirus is a major cause of morbidity in neonates. In this phase 2, placebo-controlled trial, hyperimmune globulin given to mothers with primary CMV infection at 5 to 26 weeks of gestation did not significantly alter the course of infection. Every year, approximately 0.6% of all newborns in the United States and the European Union are congenitally infected with human cytomegalovirus (CMV). 1 , 2 Approximately 20% of these infected newborns are symptomatic at birth or will have sequelae such as sensorineural hearing loss, cognitive defects, and motor defects. 3 Primary CMV infection that develops in a woman during pregnancy confers the highest risk of congenital infection and disease. 4 Identification of pregnant women with primary CMV infection is feasible by means of detection of virus-specific IgM and low IgG avidity. However, the unavailability of a therapeutic intervention of proven efficacy in the case . . .